Geron CORP 10-Q quarterly reports

Geron Corporation reported increased product revenue for Q2 2026, but continued to incur net losses, with ongoing legal proceedings and significant operating expenses posing challenges.

Geron Corporation announced its first quarter 2026 financial results, showing an increase in net product revenue for RYTELO, alongside continued investment in research and development.

Geron Corporation reported a significant increase in RYTELO product revenue for Q3 2025 and announced full enrollment in its pivotal Phase 3 IMpactMF clinical trial.

Geron Corporation reported a net loss of $16.4 million in Q2 2025, with RYTELO product revenue reaching $49.0 million, as the company continues its commercialization efforts and advances clinical trials.

Geron Corporation's Q1 2025 results reveal flat RYTELO sales growth and ongoing legal challenges, despite FDA and EC approvals.

Geron Corporation announces its Q3 2024 financial results, marked by the initial commercial launch of RYTELO and strategic financing agreements to support ongoing operations and development.

Geron Corporation announces its Q2 2024 financial results, marked by the FDA approval and initial commercial launch of RYTELO for lower-risk MDS, alongside updates on its clinical development programs.

Geron Corporation's Q1 2024 results highlight regulatory progress for imetelstat and a strong financial position bolstered by a recent public offering.